Kenvue Stock Bounces Back After Trump Links Tylenol to Autism. Here’s Why.

1. Kenvue shares rose after Trump's unproven autism claims about Tylenol. 2. Federal judge dismissed lawsuit against Tylenol for causing autism and ADHD. 3. FDA states no established causal link between Tylenol and autism risks. 4. Citi analysts noted limited legal risk for Kenvue going forward. 5. Tylenol represents about 10% of Kenvue's global sales and profits.